Mitomycin 2mg Inj 1,s

About

Mitomycin is an antineoplastic antibiotic used in chemotherapy, functioning primarily as an alkylating agent. It exerts its cytotoxic effects by cross-linking DNA, thereby inhibiting DNA, RNA, and protein synthesis, which ultimately leads to cell death. This mechanism is particularly effective against rapidly dividing cells, making it a valuable agent in the treatment of various cancers. Its action involves bioreductive activation, where it is converted into an active bifunctional or trifunctional alkylating agent that irreversibly binds to DNA, preventing replication and transcription, and thus arresting cell growth and proliferation.

Administered intravenously, Mitomycin can be used as a monotherapy or in combination with other chemotherapeutic agents or radiation therapy. Its cytotoxic effects are not cell-cycle specific, allowing it to target and kill cells in any phase of the cell cycle. Due to its potent myelosuppressive effects, vigilant monitoring of blood counts is imperative throughout the treatment course. It also carries a unique toxicity profile, including the potential for delayed bone marrow suppression and the development of hemolytic uremic syndrome.

Uses

• Treatment of advanced gastric adenocarcinoma.
• Management of pancreatic carcinoma.
• Therapy for superficial bladder cancer (intravesical administration).
• Used in combination regimens for breast cancer.

Directions For Use

Administer intravenously as directed by a healthcare professional. For bladder cancer, it may be administered intravesically.

Benefits

• Effective against various solid tumors.
• Can be used in combination chemotherapy.
• Potent cytotoxic action against cancer cells.
• Available for intravenous and intravesical administration.
• Helps to slow tumor growth and progression.
• May improve patient outcomes in specific cancers.

Side Effects

• Bone marrow suppression (leukopenia, thrombocytopenia, anemia)
• Nausea and vomiting
• Alopecia (hair loss)
• Fatigue and weakness
• Anorexia
• Stomatitis/mucositis
• Renal toxicity (hemolytic uremic syndrome)
• Pulmonary toxicity (interstitial pneumonitis)
• Extravasation at injection site
• Fever and chills
• Skin rash
• Diarrhea

Safety Measures

• Alcohol - Avoid alcohol consumption during Mitomycin treatment as it may exacerbate gastrointestinal side effects and potentially interact with the medication's metabolism.
• Pregnancy - Mitomycin is contraindicated in pregnancy due to its genotoxic and teratogenic potential. It can cause fetal harm. Effective contraception is required for both male and female patients during and after treatment.
• Breastfeeding - Breastfeeding is contraindicated during Mitomycin therapy and for a period after the last dose, as the drug is likely excreted into breast milk and could cause serious adverse effects in the infant.
• Liver - Use with caution in patients with pre-existing liver impairment. Dose adjustments may be necessary, and liver function should be closely monitored due to potential hepatotoxicity.
• Kidney - Use with extreme caution in patients with renal impairment, as Mitomycin can cause severe renal toxicity, including hemolytic uremic syndrome. Close monitoring of renal function is crucial.
• Lung - Use with caution in patients with pre-existing lung conditions, as Mitomycin can cause severe and potentially irreversible pulmonary toxicity, including interstitial pneumonitis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.